Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Kite Pharma Details CAR-T Therapy Launch, Floats Pricing Benchmarks

Executive Summary

Kite plans to initially target 72 clinical institutions experienced with CAR-T for its KTE-C19 launch, including 10 from the get-go.

Advertisement

Related Content

CAR-T Cancer Drugs Front And Center At ARM Investor Day
Cell Design Labs Envisions Robot Control of Tomorrow's CAR-T Therapies
New Interim CAR-T Data Support Kite’s BLA Submission Plans
J.P. Morgan Notebook Day 4: Kite, Cellectis and MannKind
J.P. Morgan Notebook, Jan. 15: Kite, Vivus, Amarin
J.P. Morgan Notebook, Jan. 14: AbbVie, AstraZeneca, Juno & Bluebird

Topics

Related Companies

Related Deals

What to read next

Advertisement
UsernamePublicRestriction

Register

SC097500

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

All set! This Question has been sent to my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel